Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||AMG 397 + Venetoclax|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|AMG 397||AMG-397|AMG397|Murizatoclax||MCL1 Inhibitor 18||AMG 397 is a small molecule inhibitor of MCL1 that selectively disrupts the interaction with members of the Bcl2 family, potentially resulting in increased cellular apoptosis, decreased cell viability, and reduced tumor growth (Cancer Res 2020;80(16 Suppl):Abstract nr 6218).|
|Venetoclax||Venclexta||ABT-199|RG7601|GDC-0199|ABT119|Venclyxto||BCL2 inhibitor 25||Venclexta (venetoclax) is a BH3-mimetic that binds to and inhibits BCL2, resulting in increased tumor cell apoptosis (PMID: 26589495, PMID: 25048785). Venclexta (venetoclax) is FDA approved for use in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), and in combination with chemotherapy in patients 75 years old or older with newly-diagnosed acute myeloid leukemia (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|